Amgen, Advaxis partner for worldwide cancer immunotherapies
ADXS-NEO, from Advaxis, is meant to prompt an immune response from the patient against the neoepitopes (unique mutations) that are inside the tumors within each patient.
"Amgen's collaboration with Advaxis leverages and enhances our development and commercialization expertise in novel immuno-oncology treatments," Dr. Sean Harper, executive vice president of research and development at Amgen, said. "We look forward to partnering with Advaxis to advance this highly targeted and patient-specific treatment option for patients."
Together, the two companies will unite the immune-oncology experience of Amgen with the My Immunotherapy Neo-Epitopes (MINE) program from Advaxis. This makes the companies uniquely poised to create an individualized method for treating cancer.
"Amgen is a pioneer in the science of using living cells to develop biologic medicines, making them an incredibly strong partner to develop and commercialize Advaxis' MINE," Daniel O'Connor, president and CEO of Advaxis, said. "With Amgen's resources, worldwide reach and a culture that embraces science and innovation, we are positioned to accelerate the clinical development program for ADXS-NEO to improve the lives of those who suffer from cancer."
Organizations in this story
Amgen Inc. 1 Amgen Center Dr Thousand Oaks, CA 91320